CSE: IZO
OTCQB: IZOZF
FSE: 1R3
Home
IzoView
Presentations
Fact Sheets
Media
IzoView Images
Videos
News
FAQ
For Investors
For Clinicians
For Breast Cancer Advocates
Team
Management
Advisors
Investors
Why Invest?
Stock Info
Financials
Contact
Menu
FAQ
For Clinicians
For Clinicians: Coming Soon
For Investors
For Clinicians
For Breast Cancer Advocates
IzoView
Presentations
Fact Sheets
Media
IzoView Images
Videos
News
Izotropic Provides Marketing Update
Izotropic Updates License Agreement Terms with University of California
Izotropic’s U.S. FDA Regulatory Pathway Greenlit, Company Provides Corporate Update
Izotropic Engages International Communications Consultant, Grants Incentive Stock Options & RSUs to Key Personnel, Amends Promissory Note with Primary Lender
Izotropic Completes Pre-Submission Meeting with FDA for Breast Cancer Screening Indication
Izotropic to Present at Investor Conference March 13th
FDA Sets Meeting Date with Izotropic
Izotropic Closes Non-Brokered Private Placement
Izotropic Announces Non-Brokered Private Placement- February 2025
Izotropic Reschedules Investor Conference Presentation to March 13th
Izotropic to Present at Investor Conference February 6th
Izotropic Announces Timelines and Milestones to IzoView Product Launch
Izotropic Featured in Announcement of Research and Markets’ U.S. Breast Cancer Analysis and Forecast
Izotropic Announces Team Leading Clinical Study Design and FDA Regulatory Submissions
Izotropic Files Pre-Submission with U.S. FDA for Breast Cancer Screening
Izotropic Announces AGM Results - 2024
Izotropic Provides Update On Annual General Meeting Materials and Voting Procedures
Izotropic Corporation Announces Non-Brokered Private Placement- November 2024
Izotropic Announces Regulatory Approval Plans to Launch IzoView for Breast Cancer Diagnostics in Patients with Dense Breasts in the U.S. and EU
Izotropic Amends Promissory Note Agreement With Primary Lender
Izotropic Announces Closing of First Tranche of Non-Brokered Private Placement
Izotropic Corporation Announces Non-Brokered Private Placement- June 2024
Izotropic Receives Response From U.S. FDA
Izotropic Provides Regulatory and Operational Updates
Izotropic Announces AGM Results- 2023
Izotropic Completes Pre-Submission Meeting With U.S. FDA
Izotropic Confirms FDA Pre-Submission Meeting Date
Izotropic Closes Non-Brokered Private Placement- September 2023
Izotropic Corporation Announces Non-Brokered Private Placement- September 2023
Izotropic Files Class II Pre-Submission with FDA & Releases Details On Predicate Devices
Izotropic Engages Market Awareness Consultant
Izotropic Modifies Market Approval Pathway & Strategy
Izotropic CEO Resigns
Izotropic Completes QSUB Meeting with FDA Regarding Clinical Study Acceleration
Izotropic Provides Business Update
Izotropic to Extend Period for Unsecured Loans
Izotropic’s Technical & Scientific Team Members Advocate for Commercialization of Breast CT Technology
Izotropic’s IzoView Breast CT Device To Be Featured On Advancements TV Show In USA
Izotropic Creates Compensation Committee and Adopts Charter
Izotropic Releases First Video of IzoView
Izotropic Reports Board Meeting Results
FAQ
For Investors
For Clinicians
For Breast Cancer Advocates
Team
Management
Advisors
Investors
Why Invest?
Stock Info
Financials
Contact
